Company news
Abeona Therapeutics Inc. news in 2023
Abeona Therapeutics Inc.'s news releases, calls and decks from 2023, newest first.
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
November 26, 2023
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
November 12, 2023
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
September 25, 2023
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
September 11, 2023
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
September 6, 2023
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
August 29, 2023
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
August 7, 2023
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
July 27, 2023
Abeona Therapeutics Joins Rare Disease Company Coalition
July 18, 2023
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 2, 2023
Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
June 8, 2023
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
May 21, 2023
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 15, 2023
Abeona Therapeutics Reports First Quarter 2023 Financial Results
May 10, 2023
Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting
May 10, 2023
Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 9, 2023
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
March 28, 2023
Abeona Therapeutics Announces New Employee Inducement Grants
March 23, 2023
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
March 15, 2023
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
March 13, 2023
Calls in 2023
- Abeona Therapeutics (NASDAQ:ABEO) Q3 2023 Earnings Call
Nov 13, 2023
Transcript - Abeona Therapeutics (NASDAQ:ABEO) Q2 2023 Earnings Call
Aug 8, 2023
Transcript - Abeona Therapeutics (NASDAQ:ABEO) Q1 2023 Earnings Call
May 23, 2023
Transcript - Abeona Therapeutics (NASDAQ:ABEO) Q4 2022 Earnings Call
Mar 29, 2023
Transcript